Risankizumab Shows Efficacy in Refractory Crohn's Real-World Data

Risankizumab, a selective interleukin-23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate-to-severe Crohn's disease. However, real-world data, particularly in highly refractory patient populations, have been limited.^1,2,3

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract, characterized by periods of remission and relapse. Its unpredictable nature and potential for severe complications, such as strictures, fistulas, and abscesses, significantly impact patients' quality of life. Despite the availability of various advanced therapies, including anti-TNF agents, anti-integrins, and JAK inhibitors, a substantial proportion of patients either do not respond to initial treatment (primary non-response) or lose response over time (secondary loss of response). This creates a critical need for effective alternative treatments, especially for those with highly refractory disease who have exhausted multiple therapeutic options.

Real-World Effectiveness of Risankizumab

The RISANCROHN study, derived from the ENEIDA Registry, evaluated the short-term effectiveness and outcomes at last follow-up of risankizumab in patients with refractory Crohn's disease. This study also assessed the impact of prior advanced therapy exposure.¹ Similarly, other real-world analyses have focused on endoscopic outcomes, specifically in terminal ileal lesions, to further characterize risankizumab's effectiveness.² A systematic review and meta-analysis also compiled evidence from both randomized trials and real-world settings to provide a comprehensive overview of risankizumab's efficacy and safety in Crohn's disease.³

The ENEIDA Registry, a large national registry of inflammatory bowel disease patients in Spain, provides a robust platform for real-world observational studies. Its comprehensive data collection on patient demographics, disease characteristics, treatment histories, and outcomes allows for valuable insights into the effectiveness of new therapies in routine clinical practice. The RISANCROHN study leveraged this extensive dataset to identify patients with Crohn's disease who initiated risankizumab, providing a representative sample of individuals facing significant therapeutic challenges. The focus on refractory patients, defined by prior exposure and failure to at least one advanced therapy, highlights the study's relevance to a particularly difficult-to-treat population.

In the RISANCROHN study, which included patients with highly refractory Crohn's disease, clinical remission was observed in 45.5% of patients at week 12.¹ At the last follow-up, the clinical remission rate was 53.8%.¹ Endoscopic improvement was noted in 50% of patients with terminal ileal lesions, indicating a positive impact on objective disease markers.² The effectiveness of risankizumab was maintained regardless of prior advanced therapy exposure, suggesting its utility in patients who have failed other treatments.^1,2,3

Risankizumab's mechanism of action involves selectively targeting the p19 subunit of interleukin-23 (IL-23). IL-23 plays a pivotal role in the pathogenesis of Crohn's disease by promoting the differentiation and survival of Th17 cells, which produce pro-inflammatory cytokines like IL-17 and IL-22. By inhibiting IL-23, risankizumab disrupts this inflammatory cascade, thereby reducing gut inflammation and promoting mucosal healing. This targeted approach offers a distinct advantage, particularly for patients who have not responded to therapies that target other inflammatory pathways.

The safety profile of risankizumab in these real-world settings was consistent with that observed in clinical trials. No new safety signals were identified.^1,3 The data collectively support risankizumab as an effective therapeutic option for patients with moderate-to-severe Crohn's disease, particularly those who have not responded adequately to previous advanced therapies.^1,2,3

Limitations of real-world studies typically include their observational nature and potential for confounding factors not present in controlled clinical trials. The RISANCROHN study, while providing valuable insights from a registry, shares these inherent limitations.¹ For instance, the absence of a control group in observational studies makes it challenging to definitively attribute outcomes solely to the intervention. Furthermore, variations in clinical practice across different centers contributing to the registry could introduce heterogeneity. Similarly, the real-world analysis of endoscopic outcomes, while specific, may not be generalizable to all Crohn's disease phenotypes.² Endoscopic assessment, while objective, can be influenced by the timing of the endoscopy relative to treatment initiation and the specific scoring systems used. Future research could benefit from larger, prospective real-world studies with longer follow-up periods to further confirm these findings and assess long-term outcomes, including sustained remission rates, corticosteroid-free remission, and prevention of disease complications.